Welcome to The Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference resources menu.
See below for sources that can help advance your Parkinson's research.
-
Welcome Packet
Includes: Conference Agenda, Session & Poster Abstracts, Presenter Bios
-
Landscape Intelligence Reports
MJFF provides Parkinson’s disease landscape reports to the researcher community including a target report, biomarker report, and clinical pipeline report - highlighting the latest advancements in therapeutic development.
-
Parkinson's Priority Therapeutic Clinical Pipeline Report
This report tracks therapies currently in clinical development for Parkinson’s disease as of late March 2024. It includes brief rationale and progress in key pipelines of therapeutic interest along with detailed listings of specific therapies, current development status and information about MJFF support (funding and/or non-funding connections).
-
Parkinson's Disease Biomarker Report
This report provides an overview of the Parkinson’s disease biomarkers landscape, with a focus on biochemical and molecular based assays that MJFF staff are currently monitoring. It is intended to reflect biomarkers at various stages of development and validation for the indicated intended uses (e.g., diagnosis, monitoring, etc.)
-
Parkinson's Disease Target Report
This report includes profiles of emerging and advanced targets along with a summary of the current status of the target as it relates to therapeutic devlopment, its connection to Parkinson's disease, MJFF’s investments to date and companies working on the respective target.
-
-
Targets to Therapies
MJFF's new target validation initiative, "Targets To Therapies" (T2T), seeks to increase confidence in targets prior to therapeutic development and speed the translation of promising biology into and across therapeutic pipelines. To see our exciting progress, please view T2T's poster presentation here at the conference today. Additionally, please review results from an RFI sent to the global research community earlier in 2024 with the purpose of sourcing emerging target recommendations to be evaluated within T2T.
-
Open Funding Opportunities
Learn more about our open funding opportunities.
-
Research Resources
The Michael J. Fox Foundation believes strongly in the value of open science, which is why we have assembled all of our tools and resources in one place. Join us in our efforts to cure Parkinson's disease.
-
NEW: The National Plan to End Parkinson's Act Signed Into Law
On July 2, 2024, President Biden signed the National Plan to End Parkinson’s Act into law! Learn more about ways you can connect with our Policy team to drive our initiative to prevent and cure Parkinson’s disease.
-
Connect with MJFF's Policy Team
Connect with our policy team to learn more about the Foundation's public policy and advocacy priorities.
-
Learn More About the National Parkinson's Plan
Now that the bill has been signed into law, the U.S. Department of Health and Human Services (HHS) will establish the National Parkinson’s Project, a first-ever federal initiative to prevent and cure Parkinson’s disease, treat its symptoms and slow or stop its progression. It will also establish a federal advisory council that will provide recommendations and guidance for making progress against Parkinson’s disease and atypical parkinsonisms.
-
